McKesson Corp. closed 6.64% below its 52-week high of $637.51, which the company achieved on August 2nd.

The stock's fall snapped a two-day winning streak.

Analysis of the S&P 500 health care sector's performance, quant ratings of top companies, and expert opinions on future ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Evercore ISI analyst Elizabeth Anderson CFA reiterated a Buy rating on McKesson (MCK – Research Report) yesterday and set a price target of ...

McKesson (NYSE:MCK – Get Free Report) had its price objective cut by Citigroup from $713.00 to $677.00 in a research note ...

McKesson Amplify is intended to help protect critical pharmacy services and elevate the profession by strengthening the voice ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Failed to fetch dynamically imported module: https://ca.finance.yahoo.com/assets/_app/immutable/nodes/30.B7yWvFKE.js ...

Miracle Mile Advisors LLC grew its holdings in shares of McKesson Co. (NYSE:MCK – Free Report) by 14.5% in the fourth quarter ...

The transaction enables McKesson to focus capital deployment and prioritize investments in strategic oncology and biopharma ...

Citi lowered the firm’s price target on McKesson (MCK) to $677 from $713 and keeps a Buy rating on the shares as part of a 2025 outcook for the ...